Noxxon Provides Results of Its 2022 Annual General Meeting of Shareholders

Regulatory News:

NOXXON Pharma N.V. (Euronext Growth Paris: ALNOX) (Paris:ALNOX), a biotechnology company focused on improving cancer treatments by targeting the tumor microenvironment (TME), announced today the results of its 2022 annual general meeting of shareholders (AGM), which took place on June 29, 2022, at 02.00 p.m. CEST. Shareholders representing a total of 9.33% of the total issued and outstanding share capital on June 1, 2022, were represented in person or by proxy.

All proposed resolutions submitted to the AGM were approved, including the company name change from “NOXXON Pharma N.V.” to “TME Pharma N.V.”

Aram Mangasarian, CEO of NOXXON Pharma, commented: “Our new name, TME Pharma, reflects the company’s transformation into an oncology biotech and matches our strategy to deliver best-in-class therapeutics targeting the tumor microenvironment (TME) in the most aggressive cancers. We believe that our unique approach enables anti-cancer treatment combinations that will have a greater therapeutic impact in cancer indications that respond poorly to available therapies.”

The company has reserved a new trading symbol, ALTME, and plans to submit notice of the company name change to the Euronext Growth Paris. The company expects to trade under the new symbol within the next few weeks. Until then, it intends to continue trading under its current stock symbol, ALNOX.

The full list of resolutions approved by all participating shareholders can be found below.

Item	Resolution
2.d: Adoption of the annual accounts 2021	Accepted
2.e: Release from liability of the members of the board of directors	Accepted
2.f: Release from liability of the members of the supervisory board	Accepted
3.a: Re-appointment of Dr. Aram Mangasarian as member of the board of directors	Accepted
3.b: Re-appointment of Bryan Jennings as member of the board of directors	Accepted
4.a: Re-appointment of Dr. Maurizio PetitBon as member of the supervisory board	Accepted
4.b: Re-appointment of Dr. Cornelis Alexander Izeboud as member of the supervisory board